Saturday, February 13, 2016

Fast-growing Octagon Research to be bought by Accenture

The Wayne software company that helps drug companies submit clinical data to regulators will become part of Accenture's Life Sciences industry group.

Fast-growing Octagon Research to be bought by Accenture


IPOs by Facebook and Manchester United notwithstanding, there are other ways to tap deep pockets, such as getting acquired.

Octagon Research Solutions Inc., a Wayne software company that helps pharmaceutical companies with submitting clinical data to regulators, agreed to be acquired by Accenture P.L.C. earlier this month. Terms of the transaction, which is expected to close by the end of September, were not disclosed.

At $25.5 billion in net revenues for 2011, Accenture is by far the bigger company. But Octagon has grown quickly in recent years and currently has a global workforce of 380 people, most of which work in the Philadelphia area. It also has offices in Mountain View, Calif.; London; and Bangalore, India.

David Boath, the North American managing director for Accenture’s Life Sciences industry group, said that Accenture had worked with Octagon for the last five years with several clients. “We think they have the best software to speed up the process of getting clinical data” to the Food and Drug Administration, he said.

Accenture, a consulting firm, got into the clinical data outsourcing business in 2003 when it was hired by Wyeth. In Octagon, the publicly traded company gains “a software suite we did not have before,” Boath said.

Being part of a larger organization with a stronger balance sheet should enable Octagon to handle more large pharmaceutical clients, Boath said.

Octagon was started by James C. Walker and his twin brother, Neal, in 1999. James Walker, the company’s chairman and chief executive, will remain in charge of Octagon after the transaction closes, Boath said.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter